

Foundation Medicine, Inc.  
Form SC14D9C  
February 02, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**(Rule 14d-101)**

**Solicitation/Recommendation Statement**

**Under Section 14(d)(4) of the Securities Exchange Act of 1934**

**FOUNDATION MEDICINE, INC.**

**(Name of Subject Company)**

**FOUNDATION MEDICINE, INC.**

**(Name of Person Filing Statement)**

**Common Stock, \$0.0001 par value per share**

**(Title of Class of Securities)**

**350465100**

**(CUSIP Number of Class of Securities)**

**Michael Pellini, M.D.**

**President and Chief Executive Officer**

**Foundation Medicine, Inc.**

**150 Second Street**

**Cambridge, MA 02141**

**(617) 481-2200**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications  
on Behalf of the Person Filing Statement)**

*With copies to:*

**Stuart M. Cable, Esq.**

**Lisa R. Haddad, Esq.**

**Kingsley L. Taft, Esq.**

**Goodwin Procter LLP**

**Exchange Place**

**Boston, MA 02109**

**(617) 570-1000**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications  
on Behalf of the Person Filing Statement)**

Edgar Filing: Foundation Medicine, Inc. - Form SC14D9C

- Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Item 1.01 of the amendment to the Current Report on Form 8-K filed by Foundation Medicine, Inc. on February 2, 2015 (including all exhibits attached thereto) is incorporated herein by reference.